A rich analysis of the most recent acquisition in the world of pharmaceuticals when American independent biotech giant Amgen buys biopharmaceutical company Horizon Therapeutics for close to 28 billion dollars.

The process involved a huge bidding war between Johnson & Johnson, Sanofi and Amgen who had to raise considerably its offer. Horizon is deeply involved in rare disease drug creation.

With the deal, Amgen gets its hands on thyroid eye disease drug Tepezza, chronic gout treatment Krystexxa and Uplizna, a relatively new therapy that treats neuromyelitis optica spectrum disorder.